Refine
Has Fulltext
- yes (15)
Is part of the Bibliography
- yes (15)
Year of publication
- 2021 (15) (remove)
Document Type
- Journal article (15) (remove)
Keywords
- COVID-19 (2)
- SARS-CoV-2 (2)
- metabolism (2)
- A2a-R receptor (1)
- Aspergillus fumigatus (1)
- B-cell (1)
- CETCH cycle (1)
- CO2-sequestration (1)
- Ki67 (1)
- Klimaneutralität (1)
- Klimapflanzen (1)
- Klimawandel (1)
- MHC I (1)
- MHC II (1)
- Olea (1)
- PknB (1)
- Stp (1)
- T-cell (1)
- abscisic acid (ABA) (1)
- adaptation (1)
- alveolar fibrosis (1)
- alveolar regeneration (1)
- alzheimer's disease (1)
- anticancer activity (1)
- antiproliferative (1)
- apoptosis (1)
- approved drugs (1)
- bacteriology (1)
- biofuel (1)
- biomanufacturing (1)
- bioreactor culture (1)
- calcium (1)
- carboxylation (1)
- cellular signalling networks (1)
- chemical similarity (1)
- combinatorial drug predictions (1)
- computational (1)
- computational biology and bioinformatics (1)
- cytokinin kinetin (1)
- design (1)
- docking (1)
- drug repurposing (1)
- elementary modes (1)
- encapsulation (1)
- engineering (1)
- enzyme (1)
- epitope mapping (1)
- flg22 (1)
- flux balance analysis (1)
- genus Aspergillus (1)
- guard cells (1)
- human pathogenic fungi (1)
- imaging (1)
- immunotherapies (1)
- in vivo toxicity (1)
- infection spread (1)
- invasiveness (1)
- ion signaling (1)
- lethality rate (1)
- metabolic modeling (1)
- metabolomic profiling (1)
- microbes (1)
- modular tumor tissue models (1)
- modulatory effects (1)
- molecular dynamics simulation (1)
- molecular evolution (1)
- molecular modeling (1)
- nanocarrier (1)
- network biology (1)
- olive (1)
- pH (1)
- phosphorylation (1)
- photorespiration (1)
- phylogenetic analysis (1)
- pollen tube (1)
- population coverage (1)
- positive selection (1)
- pro-oxidant (1)
- pyrazolo[3,4-d]pyrimidine (1)
- recombination (1)
- regulation (1)
- riboswitch (1)
- scaffold search (1)
- signaling pathway (1)
- spanlastic (1)
- synthetic pathways (1)
- systems biology (1)
- yvcK/glmR operon (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (15)
- Institut für Molekulare Infektionsbiologie (3)
- Kinderklinik und Poliklinik (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Frauenklinik und Poliklinik (1)
- Institut für Mathematik (1)
- Institut für Virologie und Immunbiologie (1)
- Julius-von-Sachs-Institut für Biowissenschaften (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (1)
Synthetically designed alternative photorespiratory pathways increase the biomass of tobacco and rice plants. Likewise, some in planta–tested synthetic carbon-concentrating cycles (CCCs) hold promise to increase plant biomass while diminishing atmospheric carbon dioxide burden. Taking these individual contributions into account, we hypothesize that the integration of bypasses and CCCs will further increase plant productivity. To test this in silico, we reconstructed a metabolic model by integrating photorespiration and photosynthesis with the synthetically designed alternative pathway 3 (AP3) enzymes and transporters. We calculated fluxes of the native plant system and those of AP3 combined with the inhibition of the glycolate/glycerate transporter by using the YANAsquare package. The activity values corresponding to each enzyme in photosynthesis, photorespiration, and for synthetically designed alternative pathways were estimated. Next, we modeled the effect of the crotonyl-CoA/ethylmalonyl-CoA/hydroxybutyryl-CoA cycle (CETCH), which is a set of natural and synthetically designed enzymes that fix CO₂ manifold more than the native Calvin–Benson–Bassham (CBB) cycle. We compared estimated fluxes across various pathways in the native model and under an introduced CETCH cycle. Moreover, we combined CETCH and AP3-w/plgg1RNAi, and calculated the fluxes. We anticipate higher carbon dioxide–harvesting potential in plants with an AP3 bypass and CETCH–AP3 combination. We discuss the in vivo implementation of these strategies for the improvement of C3 plants and in natural high carbon harvesters.
The present study reports the synthesis of new purine bioisosteres comprising a pyrazolo[3,4-d]pyrimidine scaffold linked to mono-, di-, and trimethoxy benzylidene moieties through hydrazine linkages. First, in silico docking experiments of the synthesized compounds against Bax, Bcl-2, Caspase-3, Ki67, p21, and p53 were performed in a trial to rationalize the observed cytotoxic activity for the tested compounds. The anticancer activity of these compounds was evaluated in vitro against Caco-2, A549, HT1080, and Hela cell lines. Results revealed that two (5 and 7) of the three synthesized compounds (5, 6, and 7) showed high cytotoxic activity against all tested cell lines with IC50 values in the micro molar concentration. Our in vitro results show that there is no significant apoptotic effect for the treatment with the experimental compounds on the viability of cells against A549 cells. Ki67 expression was found to decrease significantly following the treatment of cells with the most promising candidate: drug 7. The overall results indicate that these pyrazolopyrimidine derivatives possess anticancer activity at varying doses. The suggested mechanism of action involves the inhibition of the proliferation of cancer cells.
Plant hormones are small regulatory molecules that exert pharmacological actions in mammalian cells such as anti-oxidative and pro-metabolic effects. Kinetin belongs to the group of plant hormones cytokinin and has been associated with modulatory functions in mammalian cells. The mammalian adenosine receptor (A2a-R) is known to modulate multiple physiological responses in animal cells. Here, we describe that kinetin binds to the adenosine receptor (A2a-R) through the Asn253 residue in an adenosine dependent manner. To harness the beneficial effects of kinetin for future human use, we assess its acute toxicity by analyzing different biochemical and histological markers in rats. Kinetin at a dose below 1 mg/kg had no adverse effects on the serum level of glucose or on the activity of serum alanine transaminase (ALT) or aspartate aminotransferase (AST) enzymes in the kinetin treated rats. Whereas, creatinine levels increased after a kinetin treatment at a dose of 0.5 mg/kg. Furthermore, 5 mg/kg treated kinetin rats showed normal renal corpuscles, but a mild degeneration was observed in the renal glomeruli and renal tubules, as well as few degenerated hepatocytes were also observed in the liver. Kinetin doses below 5 mg/kg did not show any localized toxicity in the liver and kidney tissues. In addition to unraveling the binding interaction between kinetin and A2a-R, our findings suggest safe dose limits for the future use of kinetin as a therapeutic and modulatory agent against various pathophysiological conditions.
To enable a sustainable supply of chemicals, novel biotechnological solutions are required that replace the reliance on fossil resources. One potential solution is to utilize tailored biosynthetic modules for the metabolic conversion of CO2 or organic waste to chemicals and fuel by microorganisms. Currently, it is challenging to commercialize biotechnological processes for renewable chemical biomanufacturing because of a lack of highly active and specific biocatalysts. As experimental methods to engineer biocatalysts are time- and cost-intensive, it is important to establish efficient and reliable computational tools that can speed up the identification or optimization of selective, highly active, and stable enzyme variants for utilization in the biotechnological industry. Here, we review and suggest combinations of effective state-of-the-art software and online tools available for computational enzyme engineering pipelines to optimize metabolic pathways for the biosynthesis of renewable chemicals. Using examples relevant for biotechnology, we explain the underlying principles of enzyme engineering and design and illuminate future directions for automated optimization of biocatalysts for the assembly of synthetic metabolic pathways.
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indication is a more rapid and less expensive option. Therefore, we apply the scaffold searching approach based on known amyloid-beta (Aβ) inhibitor tramiprosate to screen the DrugCentral database (n = 4,642) of clinically tested drugs. As a result, menadione bisulfite and camphotamide substances with protrombogenic and neurostimulation/cardioprotection effects were identified as promising Aβ inhibitors with an improved binding affinity (ΔGbind) and blood-brain barrier permeation (logBB). Finally, the data was also confirmed by molecular dynamics simulations using implicit solvation, in particular as Molecular Mechanics Generalized Born Surface Area (MM-GBSA) model. Overall, the proposed in silico pipeline can be implemented through the early stage rational drug design to nominate some lead candidates for AD, which will be further validated in vitro and in vivo, and, finally, in a clinical trial.